Deborah Autor Sells 34,819 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Deborah Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock traded down $0.18 during mid-day trading on Tuesday, reaching $12.60. The company’s stock had a trading volume of 1,227,129 shares, compared to its average volume of 2,288,625. Amneal Pharmaceuticals, Inc. has a 1-year low of $7.02 and a 1-year high of $15.42. The company has a market cap of $3.96 billion, a P/E ratio of 33.16 and a beta of 1.32. The firm’s 50-day moving average is $12.76 and its two-hundred day moving average is $12.77.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 272.31%. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Truist Financial increased their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 target price for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMRX. Kemnay Advisory Services Inc. acquired a new stake in Amneal Pharmaceuticals in the 4th quarter valued at about $26,000. Federated Hermes Inc. increased its position in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares in the last quarter. Comerica Bank increased its position in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares in the last quarter. Spire Wealth Management increased its position in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC increased its position in Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.